AI software that estimates coronary ischemia likelihood from CT angiography without invasive testing.
Competing Products
Cleerly
Cleerly: An American digital healthcare firm focused on preventing heart attacks.
Founded
2017Cleerly: An American digital healthcare firm focused on preventing heart attacks.
Cleerly, founded with a mission to create digital care pathways to prevent heart attacks, is an American digital healthcare company. The firm leverages advanced artificial intelligence to analyze coronary computed tomography angiography (CCTA) scans, providing precision heart care at the intersection of vascular biology and AI. Cleerly's innovative approach aims to transform cardiovascular disease prevention and treatment by offering detailed insights into coronary artery health, thus enabling more effective and personalized care.
Notable figures affiliated with Cleerly include Dr. Arthur Agatston, the inventor of the Coronary Calcium Score (CACS), who has integrated Cleerly's CCTA analysis into his practice and lauds it as "dream technology." Cleerly has garnered attention for its potential to revolutionize cardiac care, earning endorsements from leading cardiologists and academic professionals. The company's AI-driven solutions have significantly impacted the way cardiovascular diseases are diagnosed and managed, positioning Cleerly as a game-changer in the digital healthcare landscape.
Companies similar to Cleerly include Elucid, Heartflow, Artrya and Caristo Diagnostics.
Cleerly was founded in 2017.
Cleerly's headquarters is located in New York City, NY, US.
Cleerly's most recent funding round was for $223M (USD) in July 2022.
As of Jul 25, 2022, Cleerly has disclosed funding of $280.5M (USD). Undisclosed round amounts are excluded.
Cleerly has 169 employees as of Feb 5, 2024.
caristo.com